Fundraising Fox

/Companies

Intelligent BIO Solutions

NASDAQ: INBS

New York, US · Delaware corporation · 36 employees on LinkedIn

Find your way into Intelligent BIO Solutions

Sign up to see every warm intro you have to Intelligent BIO Solutions

Paths you didn't know you had: your email and LinkedIn already hold routes to the Intelligent BIO Solutions team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with Google Already have an account? Log in

Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company that makes non-invasive drug testing products, including a fingerprint sweat analysis screening system and the SmarTest wearable sweat patch, to detect recent and longer-term drug use. Its products serve justice, rehabilitation, and workplace drug-screening markets and are sold across 35 countries while pursuing FDA clearance for U.S. entry.

Hardware Healthtech Medical Devices

Founders & leadership

SS

Spiro Sakiris

Spiro SakirisChief Financial Officer

HS

Harry Simeonidis

Harry Simeonidis President & CEOHarry Simeonidis joined IBS Inc. in 2017 as President before taking on the chief executive role in 2020, and concurrently served as General Manager of Farmaforce from 2017 to 2020. He spent more than a decade at GE Healthcare in roles including Master Black Belt for Asia Six Sigma, Asia Logistics Manager, ANZ/SEA Service Manager, President and CEO for Australia and New Zealand, and General Manager of Surgery for Asia Pacific.

LF

Lawrence FisherNamed on SEC filing

GM

George MargelisNamed on SEC filing

CT

Christopher TowersNamed on SEC filing

Board

JI

Jason IsenbergBoard director

SB

Steven Boyages

Steven BoyagesBoard director

JH

Jonathan HurdBoard director

NF

Nicola FraserBoard director

Reported raises · per SEC filings

Form D private placements

$28.9M disclosed across 4 of 7 rounds · 1900–2026

▶$5MraisedSep 2026 · 1 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Harry SimeonidisExecutive Officer
Spiro SakirisExecutive Officer
Steven BoyagesDirector
Jonathan HurdDirector
Jason IsenbergDirector
Nicola FraserDirector

Offering amount: $5M
Amount sold: $5M
Sales commissions: $400K
Placement agents: Ladenburg Thalmann & Co. Inc.
First sale: Aug 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedJan 2026 · 2 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Jason IsenbergDirector
Spiro SakirisExecutive Officer
Steven BoyagesDirector
Jonathan HurdDirector
Harry SimeonidisExecutive Officer
Nicola FraserDirector

Offering amount: $10M
Amount sold: $10M
Sales commissions: $900K
Placement agents: Ladenburg Thalmann & Co. Inc.
First sale: Dec 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.8MraisedAug 2025 · 7 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Steven BoyagesDirector
Jonathan HurdDirector
Spiro SakirisExecutive Officer
Harry SimeonidisExecutive Officer
Jason IsenbergDirector
Nicola FraserDirector

Offering amount: $3.8M
Amount sold: $3.8M
Sales commissions: $345.5K
Placement agents: Ladenburg Thalmann & Co. Inc.
First sale: Jul 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10.1MraisedMar 2024 · 8 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Steven BoyagesDirector
Jason IsenbergDirector
Harry SimeonidisExecutive Officer
Christopher TowersDirector
Spiro SakirisExecutive Officer
Lawrence FisherDirector
Jonathan HurdDirector

Offering amount: $10.1M
Amount sold: $10.1M
Minimum investment: $10K
Sales commissions: $910.5K
Placement agents: Ladenburg Thalmann & Co. Inc.
First sale: Mar 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶Undisclosed amountofferedOct 2022 · 36 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Lawrence FisherDirector
George MargelisDirector
Jonathan HurdDirector
Steven BoyagesExecutive Officer, Director
Spiro SakirisExecutive Officer
Harry SimeonidisExecutive Officer
Christopher TowersDirector

First sale: Oct 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.

Companies working in the same space as Intelligent BIO Solutions.

In the news

Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com · Jan 2026

Frequently asked questions

What does Intelligent BIO Solutions do?: Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company that makes non-invasive drug testing products, including a fingerprint sweat analysis screening system and the SmarTest wearable sweat patch, to detect recent and longer-term drug use. Its products serve justice, rehabilitation, and workplace drug-screening markets and are sold across 35 countries while pursuing FDA clearance for U.S. entry.
How much funding has Intelligent BIO Solutions raised?: Intelligent BIO Solutions has disclosed $28.9M raised across 4 of its 7 known rounds.
Where is Intelligent BIO Solutions headquartered?: Intelligent BIO Solutions is headquartered in New York, US.